Trump to Pfizer: Release the Vaccine Data Now

What Happened

President Trump is calling on Pfizer and other pharmaceutical companies to immediately release full data on their COVID vaccines to the public. In a recent statement, Trump said he has reviewed internal information that he described as ‘extraordinary.’ But he noted that neither the public nor the Centers for Disease Control and Prevention has been given full access to it.

He linked the lack of transparency to growing divisions within the CDC. Trump suggested that open access to the data could help restore trust and resolve ongoing internal conflicts. He stressed that the public has a right to know exactly how effective the vaccines are and what risks may be associated with them.

The push for disclosure comes amid renewed attention to vaccine policy, booster recommendations, and public confidence in federal health agencies. Trump’s comments reflect rising pressure on pharmaceutical companies to be more transparent about the studies and data used to gain regulatory approval for COVID vaccines.

Why It Matters

This is not the first time Trump has clashed with Big Pharma or criticized the handling of COVID information. However, his most recent demand for immediate public access to vaccine data is a notable shift in tone. Rather than focusing on mandates or messaging, Trump is now pressing for raw data to be released without delay.

This stock jumped 2,900%. Most investors missed it.

While Wall Street was distracted, one startup quietly built a platform with 50M+ users and landed the #1 spot on Deloitte’s list of the Fastest-Growing Software Companies.

That company is Mode Mobile – and their stock is already up 2,900% for early investors.*

By completely rethinking the $500B smartphone industry, their users have earned and saved over $325M from simply using their phones. It’s a model that’s generated $75M in revenue, and powered a jaw-dropping 32,481% growth in just 3 years.

Mode has retail deals with Walmart and Best Buy, a reserved Nasdaq ticker ($MODE), and is still offering pre-IPO shares to the public… for now.

But the last two rounds sold out fast, and space in this one is limited.

⚠️ Secure your shares now – before the potential public debut.

For many Americans, this is a welcome move. Trust in public health institutions declined in the wake of the pandemic, and conflicting guidance has left a lasting impact. By demanding transparency, Trump is speaking directly to those who feel they have been kept in the dark about the science behind vaccine decisions.

While Pfizer and other drug makers have released summaries of clinical trials and safety data, full datasets have often remained behind closed doors. Many believe that withholding this information fuels suspicion and undermines public confidence. Supporters of disclosure say that full transparency is necessary for independent review and accountability.

Opponents of Trump’s demand argue that data must be released responsibly and in context, to avoid misinterpretation. They point out that raw clinical data is complex and may not be easily understood without scientific expertise. Still, many believe that independent researchers should have access to verify claims made by pharmaceutical companies and health agencies.

How It Affects Readers

For the public, this issue centers on trust and accountability. If the data is released, it could either strengthen confidence in the vaccines or raise new questions. Regardless of the outcome, it will give people access to the same information that regulators and executives already have.

For parents, patients, and those still deciding about boosters or vaccination, this could provide more clarity. Many Americans feel they were pressured to follow recommendations without being given full information. Trump’s demand speaks to that frustration and calls for a reset in how health policy is communicated and justified.

If Trump’s call for transparency gains momentum and popularity with the public, it could push agencies like the CDC and FDA to adopt new standards for openness in public health decisions.

Transparency around vaccine data is no longer just a medical topic. It has become an integral part of how Americans assess leadership, government trust, and corporate influence.

*Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Current and historical share price(s) set by Mode Mobile.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Mode Mobile has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: https://www.sec.gov/Archives/edgar/data/1748441/000164117225025402/ex99.pdf